<?xml version="1.0" encoding="UTF-8"?>
<p id="Par5">Eligibility criteria included: age 18–78 years; a biopsy confirmed diagnosis of NHL in first or second complete or partial remission following the first-line or second-line therapy, only where the first auto-HSCT was planned; body weight ≤70 kg (rationale for weight-based measurements described in 
 <xref rid="MOESM1" ref-type="media">Supplementary methods</xref> and Supplementary Table S
 <xref rid="MOESM2" ref-type="media">1</xref>); an Eastern Cooperative Oncology Group (ECOG) performance status ≤1; at least 4 weeks since last cycle of cancer therapy including rituximab; white blood cell count &gt;2.5 × 10
 <sup>9</sup>/L; absolute neutrophil count &gt;1.5 × 10
 <sup>9</sup>/L; and platelet count &gt;100 × 10
 <sup>9</sup>/L. Patients also had to have adequate renal, hepatic, cardiac, and pulmonary function, as determined by institutional guidelines. Exclusion criteria included: failed previous HSC collections or collection attempts; prior auto-HSCT or allogeneic HSCT; treatment with granulocyte/macrophage-CSF or pegfilgrastim within 3 weeks prior, or G-CSF within 14 days prior, to study start; chronic lymphocytic leukemia; and active central nervous system malignancy.
</p>
